Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
TVTX - Travere Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$51.50
DETAILS
HIGH:
$54.00
LOW:
$49.00
MEDIAN:
$51.50
CONSENSUS:
$51.50
UPSIDE:
15.91%
Stock News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s.
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E.
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million. Travere also granted the underwriters of the.
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the “Notes”) in an underwritten offering. Travere also expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $60 million aggregate principal amount of Notes, solely to cover over-allotments. As described in more detail below, Trav.
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
Travere Therapeutics (NASDAQ:TVTX) posted a profit for the first quarter on Monday.
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.
Travere Therapeutics Reports First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its first quarter 2026 financial results and provided a corporate update. “This has been a transformative start to the year for Travere, highlighted by the landmark approval of FILSPARI in FSGS, record demand that reinforces FILSPARI's foundational position in IgAN, and the advancement of pegtibatinase with the first new patient dosed in the restarted Phase 3 HARMONY study,” said Eric Dube, Ph.D., president and.
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Travere Therapeutics to Report First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Foll.
Travere Therapeutics: Still Undervalued Post FSGS Approval
Travere Therapeutics is rated a BUY following Filspari's landmark FDA approval for FSGS, making it the only approved therapy for this indication. TVTX remains undervalued, with projected peak sales of $2.2–3B across FSGS and IgAN, and a forward PE of 8.84 versus a sector median of ~18. Filspari's commercial launch benefits from cross-selling synergies with IgAN, leveraging existing infrastructure to accelerate FSGS market penetration and reduce costs.
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?
A director of Travere Therapeutics reported selling 8,000 shares in the open market on April 14, 2026, generating a transaction value of about $329,000. The sale represented 12.21% of Gary A.
Travere Therapeutics (NASDAQ:TVTX) CAO Sells $902,595.39 in Stock
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.07, for a total value of $902,595.39. Following the sale, the chief accounting officer owned 42,353 shares in the company, valued
Travere Therapeutics (NASDAQ:TVTX) Director Sells $1,352,247.50 in Stock
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) Director Roy Baynes sold 32,750 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares of the company's
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval
Travere Therapeutics secured full FDA approval for Filspari in FSGS, expanding its rare kidney disease franchise and driving a 37% stock surge. The FSGS approval increases TVTX's U.S. addressable market by 30,000 patients, supporting a multi-year revenue and earnings inflection not yet fully reflected in estimates. Filspari's unique, non-immunosuppressive mechanism and first-mover status in FSGS position TVTX for premium pricing and significant volume-driven revenue growth.
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,420 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as.
Price Targets
Travere Therapeutics upgraded to Overweight from Neutral at Piper Sandler
$49.00
(was $41.11)
Piper Sandler
Travere Therapeutics price target raised to $54 from $49 at Guggenheim
$54.00
(was $30.70)
Guggenheim
Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX)
$49.00
(was $28.39)
Vamil Divan
·
Guggenheim
AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies
$35.00
(was $27.31)
Maury Raycroft
·
Jefferies
Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI
$33.00
(was $17.50)
Liisa Bayko
·
Evercore ISI
Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight
$27.00
(was $17.87)
Mohit Bansal
·
Wells Fargo
Travere Therapeutics price target raised to $30 from $12 at Evercore ISI
$30.00
(was $18.07)
Liisa Bayko
·
Evercore ISI
Travere Therapeutics price target raised to $20 from $18 at BofA
$20.00
(was $15.21)
Jason Zemansky
·
Bank of America Securities
Travere Therapeutics price target raised to $18 from $14 at Barclays
$18.00
(was $13.99)
Carter Gould
·
Barclays
Travere Therapeutics price target lowered to $23 from $25 at Guggenheim
$23.00
(was $15.04)
Vamil Divan
·
Guggenheim
Travere Therapeutics price target lowered to $18 from $23 at H.C. Wainwright
$18.00
(was $15.04)
Ed Arce
·
H.C. Wainwright
Travere Therapeutics (TVTX) PT Lowered to $18 at BofA Securities
$18.00
(was $14.01)
Greg Harrison
·
Bank of America Securities
Travere Therapeutics (TVTX) PT Raised to $23 at Canaccord Genuity
$23.00
(was $12.70)
Ed Nash
·
Canaccord Genuity
Guggenheim Upgrades Travere Therapeutics (TVTX) to Buy
$25.00
(was $6.31)
Vamil Divan
·
Guggenheim
Piper Sandler Reiterates Neutral Rating on Travere Therapeutics (TVTX)
$12.00
(was $8.96)
Nicole Gabreski
·
Piper Sandler
Travere Therapeutics price target raised to $20 from $19 at H.C. Wainwright
$20.00
(was $4.62)
Ed Arce
·
H.C. Wainwright
Travere Therapeutics (TVTX) PT Raised to $18 at Canaccord Genuity
$18.00
(was $3.28)
Ed Nash
·
Canaccord Genuity
Travere Therapeutics price target raised to $19 from $17 at H.C. Wainwright
$19.00
(was $2.74)
Ed Arce
·
H.C. Wainwright
Wells Fargo Initiates Coverage On Travere Therapeutics with Overweight Rating, Announces Price Target of $28
$28.00
(was $20.08)
Wells Fargo